Adelaide, Australia – Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
Australia’s impressive COVID-19 management and the world’s most attractive rebate on clinical trials costs are just a few of the reasons that make it an ideal location to restart delayed trials, according to Agilex Biolabs.
Agilex Biolabs has been open throughout the global COVID-19 pandemic. Australia had only 2 new COVID-19 cases in the past 24 hours.
Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.
Watch the BIO Digital 2020 presentation here.
The presentation by CEO Jason Valentine and moderated by VP Business Development Julia Jones details the current trials landscape in Australia and why biotechs wanting to avoid delays caused by COVID-19, can move their trials to Australia.
CEO Jason Valentine said:
“Australia has a group of proven top-tier trial providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities.”
“We have worked with all the trials service provider companies so can advise on which ones are the best fit for each study.”
“The Agilex Biolabs team can offer an unbiased approach and advice depending on specific trial requirement.”
“Biotechs are particularly attracted by Agilex Biolabs’ FDA-inspected status, and the 43.5% rebate on clinical trial spend that applies in Australia.”
“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”
Agilex Biolabs has also launched a News Video Update about COVID-19 and clinical trials in Australia. Watch here.
The company has just expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA.
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics servicesthat include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Receptor occupancy
· Cytokine release assays (whole blood or PBMC stimulation assays) and
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
The biolabs has more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.